vs

Side-by-side financial comparison of BillionToOne, Inc. (BLLN) and RadNet, Inc. (RDNT). Click either name above to swap in a different company.

RadNet, Inc. is the larger business by last-quarter revenue ($547.7M vs $83.5M, roughly 6.6× BillionToOne, Inc.). BillionToOne, Inc. runs the higher net margin — 6.8% vs -0.1%, a 6.9% gap on every dollar of revenue. On growth, BillionToOne, Inc. posted the faster year-over-year revenue change (117.4% vs 14.8%).

BillionToOne, Inc. is a life sciences and molecular diagnostics firm developing high-precision genetic testing solutions. Its core offerings include non-invasive prenatal tests, oncology diagnostics, and rare disease screening, serving clinical providers and patients mainly in North America.

RadNet is an American radiology firm. The company operates outpatient diagnostic imaging services. Headquartered in Los Angeles, California, RadNet is the largest operator of freestanding, fixed-site diagnostic imaging centers in the United States, based on the number of locations and annual imaging revenue. As of 2025, the company owns and/or operates over 400 imaging centers across Arizona, California, Delaware, Florida, Maryland, New Jersey, New York, and Texas.

BLLN vs RDNT — Head-to-Head

Bigger by revenue
RDNT
RDNT
6.6× larger
RDNT
$547.7M
$83.5M
BLLN
Growing faster (revenue YoY)
BLLN
BLLN
+102.6% gap
BLLN
117.4%
14.8%
RDNT
Higher net margin
BLLN
BLLN
6.9% more per $
BLLN
6.8%
-0.1%
RDNT

Income Statement — Q3 2025 vs Q4 2025

Metric
BLLN
BLLN
RDNT
RDNT
Revenue
$83.5M
$547.7M
Net Profit
$5.7M
$-597.0K
Gross Margin
69.9%
Operating Margin
11.5%
5.1%
Net Margin
6.8%
-0.1%
Revenue YoY
117.4%
14.8%
Net Profit YoY
138.3%
-111.2%
EPS (diluted)
$0.10
$0.00

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BLLN
BLLN
RDNT
RDNT
Q4 25
$547.7M
Q3 25
$83.5M
$522.9M
Q2 25
$498.2M
Q1 25
$471.4M
Q4 24
$477.1M
Q3 24
$38.4M
$461.1M
Q2 24
$459.7M
Q1 24
$431.7M
Net Profit
BLLN
BLLN
RDNT
RDNT
Q4 25
$-597.0K
Q3 25
$5.7M
$5.4M
Q2 25
$14.5M
Q1 25
$-37.9M
Q4 24
$5.3M
Q3 24
$-14.9M
$3.2M
Q2 24
$-3.0M
Q1 24
$-2.8M
Gross Margin
BLLN
BLLN
RDNT
RDNT
Q4 25
Q3 25
69.9%
Q2 25
Q1 25
Q4 24
Q3 24
52.6%
Q2 24
Q1 24
Operating Margin
BLLN
BLLN
RDNT
RDNT
Q4 25
5.1%
Q3 25
11.5%
5.2%
Q2 25
6.2%
Q1 25
-5.1%
Q4 24
5.1%
Q3 24
-32.9%
7.4%
Q2 24
7.6%
Q1 24
2.6%
Net Margin
BLLN
BLLN
RDNT
RDNT
Q4 25
-0.1%
Q3 25
6.8%
1.0%
Q2 25
2.9%
Q1 25
-8.0%
Q4 24
1.1%
Q3 24
-38.8%
0.7%
Q2 24
-0.6%
Q1 24
-0.6%
EPS (diluted)
BLLN
BLLN
RDNT
RDNT
Q4 25
$0.00
Q3 25
$0.10
$0.07
Q2 25
$0.19
Q1 25
$-0.51
Q4 24
$0.08
Q3 24
$-1.47
$0.04
Q2 24
$-0.04
Q1 24
$-0.04

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BLLN
BLLN
RDNT
RDNT
Cash + ST InvestmentsLiquidity on hand
$195.2M
$767.2M
Total DebtLower is stronger
$55.0M
$1.1B
Stockholders' EquityBook value
$-239.5M
$1.1B
Total Assets
$327.5M
$3.8B
Debt / EquityLower = less leverage
1.00×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BLLN
BLLN
RDNT
RDNT
Q4 25
$767.2M
Q3 25
$195.2M
$804.7M
Q2 25
$833.2M
Q1 25
$717.3M
Q4 24
$740.0M
Q3 24
$748.9M
Q2 24
$741.7M
Q1 24
$527.0M
Total Debt
BLLN
BLLN
RDNT
RDNT
Q4 25
$1.1B
Q3 25
$55.0M
$1.1B
Q2 25
$1.1B
Q1 25
$1.0B
Q4 24
$1.0B
Q3 24
$1.0B
Q2 24
$1.0B
Q1 24
$834.6M
Stockholders' Equity
BLLN
BLLN
RDNT
RDNT
Q4 25
$1.1B
Q3 25
$-239.5M
$1.1B
Q2 25
$932.3M
Q1 25
$898.1M
Q4 24
$902.3M
Q3 24
$-242.9M
$895.3M
Q2 24
$881.0M
Q1 24
$873.0M
Total Assets
BLLN
BLLN
RDNT
RDNT
Q4 25
$3.8B
Q3 25
$327.5M
$3.7B
Q2 25
$3.5B
Q1 25
$3.3B
Q4 24
$3.3B
Q3 24
$3.3B
Q2 24
$3.2B
Q1 24
$3.0B
Debt / Equity
BLLN
BLLN
RDNT
RDNT
Q4 25
1.00×
Q3 25
1.04×
Q2 25
1.18×
Q1 25
1.12×
Q4 24
1.13×
Q3 24
1.14×
Q2 24
1.17×
Q1 24
0.96×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BLLN
BLLN
RDNT
RDNT
Operating Cash FlowLast quarter
$13.8M
$84.2M
Free Cash FlowOCF − Capex
$6.5M
FCF MarginFCF / Revenue
7.7%
Capex IntensityCapex / Revenue
8.8%
Cash ConversionOCF / Net Profit
2.42×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BLLN
BLLN
RDNT
RDNT
Q4 25
$84.2M
Q3 25
$13.8M
$52.8M
Q2 25
$120.3M
Q1 25
$41.5M
Q4 24
$42.5M
Q3 24
$57.4M
Q2 24
$116.0M
Q1 24
$17.1M
Free Cash Flow
BLLN
BLLN
RDNT
RDNT
Q4 25
Q3 25
$6.5M
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
FCF Margin
BLLN
BLLN
RDNT
RDNT
Q4 25
Q3 25
7.7%
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
Capex Intensity
BLLN
BLLN
RDNT
RDNT
Q4 25
Q3 25
8.8%
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
Cash Conversion
BLLN
BLLN
RDNT
RDNT
Q4 25
Q3 25
2.42×
9.75×
Q2 25
8.33×
Q1 25
Q4 24
7.96×
Q3 24
17.89×
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BLLN
BLLN

Prenatal$74.1M89%
Oncology$8.7M10%

RDNT
RDNT

Commercial Insurance1$301.0M55%
Medicare1$129.2M24%
Capitation Arrangements$31.9M6%
Health Care Other$20.4M4%
Digital Health$16.4M3%
Other$15.2M3%
Medicaid1$14.0M3%
Workers Compensation Personal Injury1$12.3M2%
Health Care Management Service$7.5M1%

Related Comparisons